{"title":"使用调强放疗（IMRT）的术后同步放化疗治疗原发性气管癌的年轻成年男性：一个显示5年长期生存的病例报告","authors":"Xueling Chen, Xuejian Ning, Tao Si","doi":"10.1002/msp2.70006","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The incidence of primary tracheal neoplasm is extremely rare. Squamous cell carcinoma (SCC) is the most prevalent histological type of tracheal malignancy. Postoperative adjuvant radiotherapy can be considered as a curative management option. However, there are limited data available on the use of radiotherapy or concurrent chemoradiotherapy for tracheal cancer, particularly intensity-modulated radiotherapy.</p>\n </section>\n \n <section>\n \n <h3> Patient and methods</h3>\n \n <p>Herein, we present a case report of a young adult male diagnosed with primary SCC of the trachea who underwent postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT). The treatment included 50.4 Gy radiation in 28 fractions and two cycles of chemotherapy.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The patient experienced grade Ⅰ dermatitis and grade Ⅱ granulocytosis. Follow-up showed no evidence of recurrence or significant adverse effects. The patient achieved 5-year long-term survival with good quality of life.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Postoperative concurrent chemoradiotherapy using IMRT is effective for primary tracheal carcinoma, offering long-term survival and quality of life benefits.</p>\n </section>\n </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"2 2","pages":"103-109"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70006","citationCount":"0","resultStr":"{\"title\":\"Postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT) for a young adult male with primary tracheal carcinoma: A case report demonstrating 5-year long-term survival\",\"authors\":\"Xueling Chen, Xuejian Ning, Tao Si\",\"doi\":\"10.1002/msp2.70006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>The incidence of primary tracheal neoplasm is extremely rare. Squamous cell carcinoma (SCC) is the most prevalent histological type of tracheal malignancy. Postoperative adjuvant radiotherapy can be considered as a curative management option. However, there are limited data available on the use of radiotherapy or concurrent chemoradiotherapy for tracheal cancer, particularly intensity-modulated radiotherapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Patient and methods</h3>\\n \\n <p>Herein, we present a case report of a young adult male diagnosed with primary SCC of the trachea who underwent postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT). The treatment included 50.4 Gy radiation in 28 fractions and two cycles of chemotherapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The patient experienced grade Ⅰ dermatitis and grade Ⅱ granulocytosis. Follow-up showed no evidence of recurrence or significant adverse effects. The patient achieved 5-year long-term survival with good quality of life.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Postoperative concurrent chemoradiotherapy using IMRT is effective for primary tracheal carcinoma, offering long-term survival and quality of life benefits.</p>\\n </section>\\n </div>\",\"PeriodicalId\":100882,\"journal\":{\"name\":\"Malignancy Spectrum\",\"volume\":\"2 2\",\"pages\":\"103-109\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.70006\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Malignancy Spectrum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/msp2.70006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malignancy Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/msp2.70006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT) for a young adult male with primary tracheal carcinoma: A case report demonstrating 5-year long-term survival
Objective
The incidence of primary tracheal neoplasm is extremely rare. Squamous cell carcinoma (SCC) is the most prevalent histological type of tracheal malignancy. Postoperative adjuvant radiotherapy can be considered as a curative management option. However, there are limited data available on the use of radiotherapy or concurrent chemoradiotherapy for tracheal cancer, particularly intensity-modulated radiotherapy.
Patient and methods
Herein, we present a case report of a young adult male diagnosed with primary SCC of the trachea who underwent postoperative concurrent chemoradiotherapy utilizing intensity-modulated radiation therapy (IMRT). The treatment included 50.4 Gy radiation in 28 fractions and two cycles of chemotherapy.
Results
The patient experienced grade Ⅰ dermatitis and grade Ⅱ granulocytosis. Follow-up showed no evidence of recurrence or significant adverse effects. The patient achieved 5-year long-term survival with good quality of life.
Conclusion
Postoperative concurrent chemoradiotherapy using IMRT is effective for primary tracheal carcinoma, offering long-term survival and quality of life benefits.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
